항체약물접합체(ADC) 시장 규모, 점유율, 동향 분석 : 용도별, 제품별, 페이로드별, 기술별, 유통경로별, 지역별, 부문별 예측(2025-2033년)

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application, By Product, By Payload, By Technology, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,858,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,347,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,324,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

항체약물접합체(ADC) 시장 요약

세계의 항체약물접합체(ADC) 시장 규모는 2024년에 122억 6,000만 달러로 추정되며, 2033년까지 321억 1,000만 달러에 달할 것으로 예측됩니다.

2025-2033년 연평균 10.49%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이러한 성장은 주로 암 환자 증가와 전신 독성을 줄이면서 높은 효능을 제공하는 표적치료제에 대한 수요 증가에 의해 주도되고 있습니다.

항체약물접합체(ADC) 시장은 표적 치료의 발전, 임상시험 증가, 제약 기업의 전략적 투자에 힘입어 괄목할 만한 성장을 보이고 있습니다. 지속적인 연구개발 활동이 이러한 확장을 지원하고 있으며, 표적치료제와 정밀의료의 발전으로 ADC는 종양학 분야에서 우선적인 치료 옵션으로서 매력을 더해가고 있습니다. 전 세계에서 각종 암 발생률이 증가함에 따라 높은 효능을 보이면서도 부작용이 적은 치료법에 대한 수요가 증가하고 있습니다. ADC는 강력한 세포독성 약물을 암세포에 직접 전달하면서 건강한 조직을 보호함으로써 이러한 요구에 부응하고 환자의 치료 결과를 개선합니다. 임상시험 및 규제 당국의 승인 건수 증가는 제약사들이 이 새로운 치료 분야에 대한 투자를 추진하고 있는 것을 반영합니다.

예를 들어 2025년 6월 미국에서는 TROP2 단백질을 표적으로 하는 ADC '다트로웨이(다토포타맙-덱스테칸)가 기 치료 경험이 있는 성인 진행성 비소세포폐암 치료제로 승인되었습니다. 또한 2025년 2월 FDA는 내분비요법 및 화학요법 치료 경험이 있는 성인 환자의 절제 불가능한 또는 전이성 호르몬 수용체 양성 HER2 음성 유방암 치료제로 Datroway를 승인했습니다. 마찬가지로 2025년 4월, GSK는 블렌립(Blenrep)에 대한 영국 규제 당국의 승인을 획득했습니다. 이 약은 최소 1회 이상의 이전 치료를 받은 성인 다발성골수종 환자를 대상으로 다른 약제와 병용요법으로서 항체약물복합제(ADC)입니다. 이러한 발전은 항체-약물 접합체(ADC) 치료의 지속적인 성장과 효능이 입증되고 있음을 보여줍니다.

목차

제1장 분석 방법·범위

제2장 개요

제3장 항체약물접합체(ADC) 시장 : 변동 요인·동향·범위

• 시장 연관 전망
• 시장 역학
• 사업 환경 분석
  • 업계 분석 : Porter's Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석
  • 특허 만료 분석
  • 가격 분석

제4장 항체약물접합체(ADC) 시장 : 용도별 사업 분석

• 시장 점유율 : 용도별(2024년·2033년)
• 시장 규모 예측과 동향 분석 : 용도별(2021-2033년)
• 유방암
• 혈액암
• 림프종
• 백혈병
• 요로상피암
• 난소암
• 기타

제5장 항체약물접합체(ADC) 시장 : 제품별 사업 분석

• 시장 점유율 : 제품별(2024년·2033년)
• 시장 규모 예측과 동향 분석 : 제품별(2021-2033년)
• Kadcyla
• Enhertu
• Trodelvy
• Adcetris
• Polivy
• 기타

제6장 항체약물접합체 시장 : 페이로드별 사업 분석

• 시장 점유율 : 페이로드별(2024년·2033년)
• 시장 규모 예측과 동향 분석 : 페이로드별(2021-2033년)
• Auristatins
• Maytansinoids
• Calicheamicin Derivatives
• Topoisomerase I Inhibitors
• Pyrrolobenzodiazepine (PBD) Dimers
• 기타

제7장 항체약물접합체(ADC) 시장 : 기술별 사업 분석

• 시장 점유율 : 기술별(2024년·2033년)
• 시장 규모 예측과 동향 분석 : 기술별(2021-2033년)
• 절단성 링커
• 비절단성 링커
• 기타

제8장 항체약물접합체(ADC) 시장 : 유통 채널별 사업 분석

• 시장 점유율 : 유통 채널별(2024년·2033년)
• 시장 규모 예측과 동향 분석 : 유통 채널별(2021-2033년)
• 병원 약국
• 전문 약국
• 기타

제9장 항체약물접합체(ADC) 시장 : 지역별 추정·동향 분석

• 시장 점유율 분석 : 지역별(2024년·2033년)
• 시장 대시보드 : 지역별
• 시장 규모 예측과 동향 분석(2021-2033년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제10장 경쟁 구도

• 참여 기업의 개요
• 기업의 시장 현황 분석
• 기업 분류
• 전략 지도제작
• 기업 개요/리스트
  • Seagen, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Gilead Sciences, Inc.
  • Daiichi Sankyo Company Ltd.
  • antibody drug conjugates Therapeutics SA

KSA

영문 목차

영문목차

Antibody Drug Conjugates Market Summary

The global antibody drug conjugates market size was estimated at USD 12.26 billion in 2024 and is projected to reach USD 32.11 billion by 2033, growing at a CAGR of 10.49% from 2025 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for targeted therapies that offer greater efficacy with reduced systemic toxicity.

The antibody-drug conjugates (ADC) market is experiencing significant growth, driven by advancements in targeted therapies, increasing clinical trials, and strategic investments by pharmaceutical companies. Ongoing research and development activities support this expansion, with ongoing advancements in targeted therapy and precision medicine increasing the appeal of ADCs as a preferred treatment option in oncology. The rising global incidence of various cancer types has created a demand for therapies that offer high efficacy with fewer adverse effects. ADCs address this need by delivering potent cytotoxic agents directly to cancer cells while sparing healthy tissues, thereby improving patient outcomes. The increasing number of clinical trials and regulatory approvals reflects the commitment of pharmaceutical companies to invest in this novel treatment class.

For instance, in June 2025, the U.S. approved Datroway (datopotamab deruxtecan), an ADC targeting the TROP 2 protein, for the treatment of advanced non-small cell lung cancer in adults who had previously undergone treatment. Additionally, in February 2025, the FDA approved Datroway for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer in adults who had undergone prior endocrine-based therapy and chemotherapy. Similarly, in April 2025, GSK received UK regulatory approval for Blenrep, an ADC for the treatment of adults with multiple myeloma in combination with another medication after at least one prior therapy. These developments highlight the continued growth and validation of ADC therapies.

Global Antibody Drug Conjugates Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antibody drug conjugates market report based on application, product, payload, technology, distribution channel, and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Breast Cancer
• Blood Cancer
  • Lymphoma
  • Leukemia
• Urothelial Carcinoma
• Ovarian Cancer
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Kadcyla (ado-trastuzumab emtansine)
• Enhertu (trastuzumab deruxtecan)
• Trodelvy (sacituzumab govitecan)
• Adcetris (brentuximab vedotin)
• Polivy (polatuzumab vedotin)
• Others (Padcev, Tivdak, Elahere, Zynlonta, Mylotarg, Besponsa)
• Payload Outlook (Revenue, USD Million, 2021 - 2033)
• Auristatins (MMAE, MMAF)
• Maytansinoids (DM1, DM4)
• Calicheamicin Derivatives
• Topoisomerase I Inhibitors (SN-38, DXd)
• Pyrrolobenzodiazepine (PBD) Dimers
• Others
• TechnologyOutlook (Revenue, USD Million, 2021 - 2033)
• Cleavable Linker
• Non-Cleavable Linker
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacy
• Specialty Pharmacy
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Product
  • 1.2.3. Payload
  • 1.2.4. Technology
  • 1.2.5. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Antibody Drug Conjugates Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Antibody Drug Conjugates Market: Application Business Analysis

• 4.1. Application Market Share, 2024 & 2033
• 4.2. Application Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 4.4. Breast Cancer
  • 4.4.1. Breast Cancer Market, 2021 - 2033 (USD Million)
• 4.5. Blood Cancer
  • 4.5.1. Blood Cancer Market, 2021 - 2033 (USD Million)
• 4.6. Lymphoma
  • 4.6.1. Lymphoma Market, 2021 - 2033 (USD Million)
• 4.7. Leukemia
  • 4.7.1. Leukemia Market, 2021 - 2033 (USD Million)
• 4.8. Urothelial Carcinoma
  • 4.8.1. Urothelial Carcinoma Market, 2021 - 2033 (USD Million)
• 4.9. Ovarian Cancer
  • 4.9.1. Ovarian Cancer Market, 2021 - 2033 (USD Million)
• 4.10. Others
  • 4.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Antibody Drug Conjugates Market: Product Business Analysis

• 5.1. Product Market Share, 2024 & 2033
• 5.2. Product Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 5.4. Kadcyla
  • 5.4.1. Kadcyla Market, 2021 - 2033 (USD Million)
• 5.5. Enhertu
  • 5.5.1. Enhertu Market, 2021 - 2033 (USD Million)
• 5.6. Trodelvy
  • 5.6.1. Trodelvy Market, 2021 - 2033 (USD Million)
• 5.7. Adcetris
  • 5.7.1. Adcetris Market, 2021 - 2033 (USD Million)
• 5.8. Polivy
  • 5.8.1. Polivy Market, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Antibody Drug Conjugates Market: Payload Business Analysis

• 6.1. Payload Market Share, 2024 & 2033
• 6.2. Payload Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by payload, 2021 to 2033 (USD Million)
• 6.4. Auristatins
  • 6.4.1. Auristatins Market, 2021 - 2033 (USD Million)
• 6.5. Maytansinoids
  • 6.5.1. Maytansinoids Market, 2021 - 2033 (USD Million)
• 6.6. Calicheamicin Derivatives
  • 6.6.1. Calicheamicin Derivatives Market, 2021 - 2033 (USD Million)
• 6.7. Topoisomerase I Inhibitors
  • 6.7.1. Topoisomerase I Inhibitors Market, 2021 - 2033 (USD Million)
• 6.8. Pyrrolobenzodiazepine (PBD) Dimers
  • 6.8.1. Pyrrolobenzodiazepine (PBD) Dimers Market, 2021 - 2033 (USD Million)
• 6.9. Others
  • 6.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Antibody Drug Conjugates Market: Technology Business Analysis

• 7.1. Technology Market Share, 2024 & 2033
• 7.2. Technology Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by technology, 2021 to 2033 (USD Million)
• 7.4. Cleavable Linker
  • 7.4.1. Cleavable Linker Market, 2021 - 2033 (USD Million)
• 7.5. Non- cleavable Linker
  • 7.5.1. Non- cleavable Linker Market, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Antibody Drug Conjugates Market: Distribution Channel Business Analysis

• 8.1. Distribution Channel Market Share, 2024 & 2033
• 8.2. Distribution Channel Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
• 8.4. Hospital Pharmacy
  • 8.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
• 8.5. Specialty Pharmacy
  • 8.5.1. Specialty Pharmacy Market, 2021 - 2033 (USD Million)
• 8.6. Others
  • 8.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 9. Antibody Drug Conjugates Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2033
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 9.4. North America
  • 9.4.1. North America Antibody Drug Conjugates Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Reimbursement Framework
    • 9.4.2.5. U.S. Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Reimbursement Framework
    • 9.4.3.5. U.S. Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Reimbursement Framework
    • 9.4.4.5. Mexico Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Reimbursement Framework
    • 9.5.2.5. Uk Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Reimbursement Framework
    • 9.5.3.5. Germany Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Target Disease Prevalence
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. Reimbursement Framework
    • 9.5.4.5. France Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Target Disease Prevalence
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Reimbursement Framework
    • 9.5.5.5. Italy Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Target Disease Prevalence
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Reimbursement Framework
    • 9.5.6.5. Spain Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. Denmark
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Target Disease Prevalence
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. Reimbursement Framework
    • 9.5.7.5. Denmark Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Target Disease Prevalence
    • 9.5.8.3. Regulatory Framework
    • 9.5.8.4. Reimbursement Framework
    • 9.5.8.5. Sweden Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.9. Norway
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Target Disease Prevalence
    • 9.5.9.3. Regulatory Framework
    • 9.5.9.4. Reimbursement Framework
    • 9.5.9.5. Norway Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Reimbursement Framework
    • 9.6.2.5. Japan Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Reimbursement Framework
    • 9.6.3.5. China Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Reimbursement Framework
    • 9.6.4.5. India Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Reimbursement Framework
    • 9.6.5.5. Australia Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Target Disease Prevalence
    • 9.6.6.3. Regulatory Framework
    • 9.6.6.4. Reimbursement Framework
    • 9.6.6.5. South Korea Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Target Disease Prevalence
    • 9.6.7.3. Regulatory Framework
    • 9.6.7.4. Reimbursement Framework
    • 9.6.7.5. Thailand Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Target Disease Prevalence
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. Reimbursement Framework
    • 9.7.2.5. Japan Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Target Disease Prevalence
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Reimbursement Framework
    • 9.7.3.5. China Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.8. Middle East and Africa
  • 9.8.1. Middle East and Africa Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Target Disease Prevalence
    • 9.8.2.3. Regulatory Framework
    • 9.8.2.4. Reimbursement Framework
    • 9.8.2.5. South Africa Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Target Disease Prevalence
    • 9.8.3.3. Regulatory Framework
    • 9.8.3.4. Reimbursement Framework
    • 9.8.3.5. Saudi Arabia Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Target Disease Prevalence
    • 9.8.4.3. Regulatory Framework
    • 9.8.4.4. Reimbursement Framework
    • 9.8.4.5. UAE Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Target Disease Prevalence
    • 9.8.5.3. Regulatory Framework
    • 9.8.5.4. Reimbursement Framework
    • 9.8.5.5. Kuwait Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Seagen, Inc.
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Application Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. Takeda Pharmaceutical Company Ltd.
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Application Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. AstraZeneca
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Application Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. F. Hoffmann-La Roche Ltd.
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Application Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. Pfizer, Inc.
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Application Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Gilead Sciences, Inc.
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Application Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. Daiichi Sankyo Company Ltd.
    • 10.5.7.1. Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Application Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. antibody drug conjugates Therapeutics SA
    • 10.5.8.1. Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Application Benchmarking
    • 10.5.8.4. Strategic Initiatives

관련자료